Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

IOTA ADNEX Model (iModel) for Ovarian Tumours

The IOTA ADNEX model calculates the probability that an adnexal mass is benign, borderline, stage I cancer, stage II-IV cancer, or a secondary metastatic tumour, using ultrasound and clinical features.

Evidence-based context for fast calculator use

Purpose:
Differentiate between benign and malignant adnexal masses to guide surgical planning
Population:
Women with adnexal masses evaluated by ultrasound
Factors:
Age, Serum CA-125, Maximum lesion diameter, Proportion solid tissue, Number of papillary projections, More than 10 cyst locules, Acoustic shadows, Ascites, Oncology centre
Reference:
Van Calster et al., BMJ 2014
HomeiMODEL (Ovarian Recurrence)
Pin your most used calculators here by clicking the star in the dropdown.

iMODEL (Ovarian Recurrence)

Clinical Context & Background

The iMODEL (International Model) score estimates the probability of complete cytoreduction (R0) in patients with platinum-sensitive recurrent ovarian cancer. It provides a more granular risk assessment than the binary AGO score.
Primary Source EvidenceSehouli J, Fotopoulou C, Harter P, et al. A risk model for prediction of complete secondary cytoreductive surgery in recurrent ovarian cancer. Int J Gynecol Cancer. 2012;22(Suppl 3):E377.
Formula Logic
Sum of 6 risk factors. Max 11.9.

Reference Data

Total ScoreEst. Complete Resection Rate
Low Risk (≤ 4.7)83% - 94%
Intermediate60% - 80%
High Risk (> 4.7)Low

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use iMODEL (Ovarian Recurrence) when iMODEL Score — predict complete cytoreduction (R0) probability in platinum-sensitive recurrent ovarian cancer. 6-factor risk model.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk (≤ 4.7) through High Risk (> 4.7).
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm organ site, pathology, menopausal or postoperative context, imaging, biomarker assay, and specialist referral pathway.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Adnexal-mass, cervical postoperative, endometrial, and ovarian cytoreduction models answer different clinical questions.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment

How to apply this result

For a representative case, verify FIGO Stage at Diagnosis, Residual Disease at Primary Surgery, Platinum-Free Interval, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Gynecologic Oncology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

FIGO GTN Risk ScoreRMI (Risk of Malignancy Index)ROMA Score (Ovarian)

Frequently Asked Questions

When should iMODEL (Ovarian Recurrence) be used?

Use it for patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment when all required inputs and the intended clinical setting are confirmed.

Can iMODEL (Ovarian Recurrence) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.